The specter of generic competition has long loomed above copyright’s iconic drug, Sildenafil, raising questions about the prospects of connected drug stakes. While early times saw significant gains, the intellectual property lapse has allowed the door for discounted copies, potentially lowering profitability and presenting a genuine hazard for in